Table 1.

Characteristics of the selected studies.

Study, Year	Country	Rebamipide-Containing Regimen(s)	Comparison Regimen(s)
Saita et al. [26]	Japan	Dual therapy—2 weeks (w); rebamipide—8 w	Dual therapy—2 w
Hahm et al. [27]	Korea	Dual therapy—2 w; rebamipide—2 w	Dual therapy—2 w
Nebiki et al. [28]	Japan	Dual therapy—2 w; rebamipide—2 w	Dual therapy—2 w
Kato et al. [29]	Japan	Dual therapy—2 w; rebamipide—8 w	Dual therapy—2 w; teprenone—8 w
Kimura et al. [30]	Japan	Triple therapy—1 w; rebamipide—12 w	Triple therapy—1 w; teprenone—12 w
Lee et al. [31]	Korea	Triple therapy—2 w; rebamipide—2 w	Triple therapy—2 w
Fujioka et al. [32]	Japan	Dual therapy—2 w; rebamipide—8 w	Dual therapy—2 w
Simanenkov et al. [33]	Russia	Triple therapy with bismuth—10 days (d); rebamipide—4 w	Triple therapy—10 d
			Triple therapy with bismuth—10 d
Kim et al. [34]	Korea	Concomitant therapy—10 d; rebamipide—10 d	Concomitant therapy—10 d
			Concomitant therapy—10 d; ecabet—10 d
Dicheva et al. [35]	Russia	Triple therapy—10 d; rebamipide—10 d	Triple therapy—10 d
Andreev et al. [36]	Russia	Triple therapy—10 d; rebamipide—10 d	Triple therapy—10 d
		Triple therapy—10 d; rebamipide—4 w